Nurix Therapeutics
NRIX
175 hedge funds and large institutions have $1.53B invested in Nurix Therapeutics in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 66 increasing their positions, 47 reducing their positions, and 31 closing their positions.
771% more call options, than puts
Call options by funds: $7.17M | Put options by funds: $823K
180% more capital inflows, than outflows
Capital inflows: $476M | Capital outflows: $170M
40% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 47
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
16% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 31
2% more funds holding
Funds holding: 172 → 175 (+3)
1.49% more ownership
Funds ownership: 105.38% → 106.88% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$230M |
| 2 |
Commodore Capital
New York
|
+$30.9M |
| 3 |
RA Capital Management
Boston,
Massachusetts
|
+$30.6M |
| 4 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$23.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
-$19.9M |
| 2 |
ARK Investment Management
St. Petersburg,
Florida
|
-$15.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$15.6M |
| 4 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$9.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$8.28M |
NRIX Hedge Fund Activity: Q4 2024 in Review
175 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q4 2024, worth a combined $1.53B — up 0.17% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new NRIX positions and 31 closed out — a net gain of 5 holders — while 66 added to existing stakes and 47 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $230M. The largest seller was Deep Track Capital, cutting an estimated $19.9M.
- 175 institutional investors held Nurix Therapeutics (NRIX) as of Q4 2024, up from 172 in Q3 2024.
- Funds reported $1.53B of Nurix Therapeutics stock for Q4 2024, up 0.17% quarter-over-quarter.
- 36 funds opened new Nurix Therapeutics positions in Q4 2024 and 31 closed out, a net change of +5 holders.
- The largest Nurix Therapeutics buyer in Q4 2024 was Fidelity Investments, an estimated $230M added.
- The largest Nurix Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $19.9M sold.
Based on aggregated 13F filings for Q4 2024.